jRCT2031220567进行中（未招募）不适用
A Phase II/III, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study of M610101 in Patients with Atopic Dermatitis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 270
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 12age old over 至 No limit（—）
- 性别
- All
入选标准
- •Patients with atopic dermatitis over 12 years old
- •Patients with an IGA score of 2 or 3 for atopic dermatitis
排除标准
- •Patients complicated with diseases considered inappropriate for participation in clinical trials such as serious cardiac / hepatic / renal / pulmonary / hematologic disease
- •Patients with skin diseases other than atopic dermatitis that affect the evaluation of atopic dermatitis or the safety of the subject
结局指标
主要结局
-
Proportion of participants achieving IGA score of 0 or 1 with improvement from baseline at week 8
次要结局
未报告次要终点
研究者
相似试验
招募中
3 期
A Phase III Long-Term Study of M610101 in Patients with Atopic DermatitisAtopic dermatitisJPRN-jRCT2031220566Tomoyuki Nishiura200
未知
2 期
A M117101 phase II study in patients with primary palmar hyperhidrosisprimary palmar hyperhidrosisJPRN-jRCT2080222374Maruho Co.,Ltd.
进行中（未招募）
不适用
A Phase II Study of PHA-739358 in Patients with Metastatic Hormone Refractory Prostate Cancer. - NDTreatment of patients with metastatic hormone refractory prostate cancer.MedDRA version: 9.1Level: LLTClassification code 10036909Term: Prostate cancer metastaticEUCTR2006-006136-21-ITERVIANO MEDICAL SCIENCES118
进行中（未招募）
1 期
A Phase II Study of PHA-739358 in Patients with Metastatic Hormone Refractory Prostate Cancer. - not availableMetastatic hormone refractory prostate cancerMedDRA version: 9.1Level: LLTClassification code 10062904Term: Hormone-refractory prostate cancerEUCTR2006-006136-21-FRerviano Medical Sciences S.r.l.118
已完成
2 期
A Phase II Study of PHA-739358 in Patients with Metastatic Hormone Refractory Prostate Cancer.HRPC/ hormone refractory prostate carcinoma10036958NL-OMON31740erviano Medical Sciences Srl, Italy10